Guardant Health has its sights set on redefining how people get checked for colorectal cancer, and its blood test for catching stray tumor DNA soon has a date with the FDA.
The agency has scheduled an advisory panel meeting May 23 to help evaluate the company’s Shield test, which…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
